Neeraj Bajpai is a seasoned healthcare professional with nearly two decades of comprehensive experience in general management, sales, and marketing, particularly within the pharmaceutical industry. Currently serving as the Associate Business Director at Abbott India Limited, Neeraj is at the helm of business operations for...
Neeraj Bajpai is a seasoned healthcare professional with nearly two decades of comprehensive experience in general management, sales, and marketing, particularly within the pharmaceutical industry. Currently serving as the Associate Business Director at Abbott India Limited, Neeraj is at the helm of business operations for the Metabolics and Miliana Business Units, wielding P&L responsibility that underscores his strategic leadership capabilities. His role involves managing a flagship thyroid portfolio valued at $60 million, which includes the renowned Thyronorm brand—one of the top contenders in the Indian pharmaceutical market.
Neeraj’s expertise extends to market shaping and the implementation of Customer Relationship Management (CRM) programs, which are pivotal in driving sales effectiveness and enhancing customer engagement. Under his guidance, a dedicated team of 430 professionals is focused on delivering innovative solutions and improving patient outcomes in the metabolic health sector. Additionally, Neeraj is instrumental in advancing menopause hormone therapy through the Miliana team, particularly with the Femoston brand, which is gaining traction in a critical area of women’s health.
His skill set is robust, encompassing product management, competitive analysis, and cross-functional relationship building, which are essential for navigating the complexities of the healthcare landscape. Neeraj’s commitment to mentoring and coaching emerging leaders further highlights his dedication to fostering talent within the industry. With a keen eye for competitive intelligence and global marketing strategies, Neeraj Bajpai is not only shaping the future of Abbott India but also contributing significantly to the broader healthcare ecosystem in South Asia.
